Trials / Completed
CompletedNCT01321567
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,157 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rabeprazole sodium | Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury. |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2013-03-01
- Completion
- 2013-08-01
- First posted
- 2011-03-23
- Last updated
- 2023-07-24
Locations
447 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01321567. Inclusion in this directory is not an endorsement.